Skip to main content
. 2023 Mar 12;15(3):924. doi: 10.3390/pharmaceutics15030924

Table 1.

Demographic and clinical variables for the participants’ groups.

Variable AD (n = 223) Control (n = 57)
Age (years, median (IQR)) 71 (67.5, 74) 65 (62, 69)
Sex (female, n (%)) 135 (60.54%) 25 (43.86%)
CSF biomarkers
Aß42 levels (pg/mL, median (IQR)) 600 (468.04, 702.1) 1206.15 (996, 1472)
t-tau levels (pg/mL, median (IQR)) 586 (414, 837) 240 (182, 313)
p-tau levels (pg/mL, median (IQR)) 92 (72.5, 131) 42 (32, 56)
Ratio t-tau/Aß42 (median (IQR)) 0.94 (0.68, 1.43) 0.19 (0.14, 0.24)
Smoking history
No (n, %) 145 (65.02%) 34 (59.65%)
No (Ex-smoker), (n, %) 45 (20.18%) 10 (17.54%)
Yes (n, %) 33 (14.8%) 13 (22.81%)
Number of concomitant medications 5 (3, 7) 3 (2, 5)
Total cholesterol (mg/dL, median (IQR)) 189 (165.25, 212) 196 (170, 222)
HDL cholesterol (mg/dL, median (IQR)) 55.5 (47, 66.25) 55 (44, 67.6)
Lipid-modifying agents (n, %) 123 (55.16%) 28 (49.12%)
Antidiabetic drugs (n, %) 36 (16.14%) 11 (19.3%)
Systolic blood pressure (mmHg, median (IQR)) 135 (124.58, 143.42) 130 (118, 139)
Diastolic blood pressure (DBP) (mmHg, median (IQR)) 75 (70, 81) 78 (71, 82.5)
Hypertension (n, %) 122 (54.71%) 30 (52.63%)

Aß42 = ß amyloid 42; CSF = cerebrospinal fluid; dL = deciliter; IQR = interquartile range; mg = milligrams; mL = milliliters; mmHg = millimeters of mercury; n = number of patients; pg = picograms; p-tau = phosphorylated tau; t-tau = total tau.